Atypical Abruptio Placentae with AKI: Interventional Dilemma

Introduction: Alterations in the complement cascade can affect many organs and lead to renal, hematological, or obstetric complications. Here, we present a case of pregnancy complicated by abruptio placentae and severe acute kidney injury (AKI) requiring dialysis, where we identified a genetic predisposition to complement dysregulation. Case Description: A 37-year-old female G5P3 at 36 weeks pregnancy, presented to the ER with abdominal pain. Fetal bradycardia was detected, prompting an urgent C-section. During surgery, placental abruption was diagnosed, she became hypotensive, requiring 2 liters of blood products. Post-surgery, she was anuric despite intravenous fluids and resolution of hypotension. Laboratory results were notable for AKI (Cr 2.2), transaminitis, anemia (Hb 7.6), thrombocytopenia (Plt 80), low haptoglobin, fibrinogen of 422md/dl and very elevated lactate dehydrogenase (LDH) at 3080U/L. The peripheral blood smear showed few schistocytes. Complement levels and ADAMTS13 were unremarkable. Hemodialysis was initiated on day 2. The clinical diagnosis was thrombotic microangiopathy (TMA) secondary to either HELLP syndrome vs atypical hemolytic uremic syndrome (aHUS). Eculizumab was considered but not given as her hematologic parameters rapidly improved. Two weeks later, she remained dialysis dependent. Three weeks after admission results of genetic testing for complement pathway related genes, revealed homozygous bi-allelic loss of Complement Factor H (CFHR3 – CFHR1) genes, which has been recently categorized as pathogenic. Eculizumab was then started. Her renal function improved, and she successfully transitioned off dialysis. Discussion: Despite carrying pathogenic variants associated with complement dysregulation, many patients remain asymptomatic for most of their lives. Several conditions, including pregnancy, can precipitate episodes of TMAs, which can be mistaken for preeclampsia. Advances in complement genetics have transformed our understanding of TMAs, but interpreting complement genetics is complex and often requires expertise from geneticists and complement biology specialists. This case illustrates the need to remain vigilant about atypical obstetric complications, as adequate treatment of aHUS can prevent irreversible renal injury.

Authors

Institutions

Publication Details

Journal
Journal of the American Society of Nephrology
Published
2024-10-01
DOI
https://doi.org/10.1681/asn.2024jdm5f5aa
Primary Topic
Maternal and fetal healthcare
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Atypical Abruptio Placentae with AKI: Interventional Dilemma

Benjamin D. Humphreys, Ignacio A. Portales Castillo, Muhammad Yasir Baloch
Journal of the American Society of Nephrology
Maternal and fetal healthcare
article

Atypical Abruptio Placentae with AKI: Interventional Dilemma

Benjamin D. Humphreys, Ignacio A. Portales Castillo, Muhammad Yasir Baloch
article en

Abstract

Introduction: Alterations in the complement cascade can affect many organs and lead to renal, hematological, or obstetric complications. Here, we present a case of pregnancy complicated by abruptio placentae and severe acute kidney injury (AKI) requiring dialysis, where we identified a genetic predisposition to complement dysregulation. Case Description: A 37-year-old female G5P3 at 36 weeks pregnancy, presented to the ER with abdominal pain. Fetal bradycardia was detected, prompting an urgent C-section. During surgery, placental abruption was diagnosed, she became hypotensive, requiring 2 liters of blood products. Post-surgery, she was anuric despite intravenous fluids and resolution of hypotension. Laboratory results were notable for AKI (Cr 2.2), transaminitis, anemia (Hb 7.6), thrombocytopenia (Plt 80), low haptoglobin, fibrinogen of 422md/dl and very elevated lactate dehydrogenase (LDH) at 3080U/L. The peripheral blood smear showed few schistocytes. Complement levels and ADAMTS13 were unremarkable. Hemodialysis was initiated on day 2. The clinical diagnosis was thrombotic microangiopathy (TMA) secondary to either HELLP syndrome vs atypical hemolytic uremic syndrome (aHUS). Eculizumab was considered but not given as her hematologic parameters rapidly improved. Two weeks later, she remained dialysis dependent. Three weeks after admission results of genetic testing for complement pathway related genes, revealed homozygous bi-allelic loss of Complement Factor H (CFHR3 – CFHR1) genes, which has been recently categorized as pathogenic. Eculizumab was then started. Her renal function improved, and she successfully transitioned off dialysis. Discussion: Despite carrying pathogenic variants associated with complement dysregulation, many patients remain asymptomatic for most of their lives. Several conditions, including pregnancy, can precipitate episodes of TMAs, which can be mistaken for preeclampsia. Advances in complement genetics have transformed our understanding of TMAs, but interpreting complement genetics is complex and often requires expertise from geneticists and complement biology specialists. This case illustrates the need to remain vigilant about atypical obstetric complications, as adequate treatment of aHUS can prevent irreversible renal injury.

Journal of the American Society of NephrologyVol. 35(10S)
Washington University in St. Louis (US)
Openalex Percentile: Top 70%
Maternal and fetal healthcare
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.